• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:03:24 PM ET
    $GNCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNCA alert in real time by email
    SC 13G/A 1 sc13ga307422gnca_02122021.htm AMENDMENT NO. 3 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 3)1

     

    Genocea Biosciences, Inc.

     (Name of Issuer)

    Common Stock, $0.001 par value

     (Title of Class of Securities)

    372427401

     (CUSIP Number)

    December 31, 2020

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,786,937 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              2,786,937 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,786,937 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.32% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 147,648 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by BVF. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 103,395 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by BVF. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 252,407 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by BVF. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 1,479,683 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by BVF.

     

    Excludes 284,862 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by BVF.

    2

    CUSIP No. 372427401

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,786,937 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              2,786,937 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,786,937 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.32% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 147,648 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by BVF. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 103,395 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by BVF. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 252,407 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by BVF. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 1,479,683 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by BVF.

     

    Excludes 284,862 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by BVF.

    3

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,984,476 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,984,476 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,984,476 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.81% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 98,640 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by BVF2. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 93,331 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by BVF2. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 227,841 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by BVF2. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Excludes 1,234,286 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by BVF2.

     

    Excludes 174,151 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by BVF2.

    4

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,984,476 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,984,476 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,984,476 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.81% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 98,640 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by BVF2. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 93,331 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by BVF2. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 227,841 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by BVF2. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Excludes 1,234,286 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by BVF2.

     

    Excludes 174,151 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by BVF2.

    5

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         347,804 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              347,804 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            347,804 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 25,318 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by Trading Fund OS. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 13,350 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by Trading Fund OS. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 32,590 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by Trading Fund OS. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Excludes 208,701 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by Trading Fund OS.

     

    Excludes 37,426 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by Trading Fund OS.

    6

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         347,804 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              347,804 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            347,804 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1% (1)  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    (1) Includes 25,318 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by Trading Fund OS. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 13,350 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by Trading Fund OS. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 32,590 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by Trading Fund OS. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Excludes 208,701 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by Trading Fund OS.

     

    Excludes 37,426 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by Trading Fund OS.

    7

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,771,413 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              4,771,413 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,771,413 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.04% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 147,648 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by BVF and 98,640 shares of Common Stock underlying certain Warrants owned by BVF2. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 103,395 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by BVF and 93,331 shares of Common Stock underlying certain B Warrants owned by BVF2. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 252,407 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by BVF and 227,841 shares of Common Stock underlying certain Pre-Funded B Warrants owned by BVF2. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 1,479,683 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by BVF and 1,234,286 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker owned by BVF2.

     

    Excludes 284,862 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by BVF and 174,151 shares of Common Stock underlying certain Pre-Funded C Warrants due to the Pre-Funded C Warrants Blocker owned by BVF2.

    8

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,285,549 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              5,285,549 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,285,549 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.99% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    (1) Includes 312,498 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by the Reporting Persons. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 217,617 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by the Reporting Persons. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 531,248 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by the Reporting Persons. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 2,939,478 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

     

    Excludes 500,000 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

    9

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,285,549 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              5,285,549 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,285,549 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.99% (1)  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    (1) Includes 312,498 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by the Reporting Persons. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 217,617 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by the Reporting Persons. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 531,248 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by the Reporting Persons. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 2,939,478 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

     

    Excludes 500,000 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

    10

    CUSIP No. 372427401

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,285,549 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              5,285,549 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,285,549 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.99% (1)  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    (1) Includes 312,498 shares of Common Stock underlying certain Warrants (defined in Item 4) owned by the Reporting Persons. The Warrants are subject to the Warrants Blocker (defined in Item 4).

     

    Includes 217,617 shares of Common Stock underlying certain B Warrants (defined in Item 4) owned by the Reporting Persons. The B Warrants are subject to the B Warrants Blocker (defined in Item 4).

     

    Includes 531,248 shares of Common Stock underlying certain Pre-Funded B Warrants (defined in Item 4) owned by the Reporting Persons. The Pre-Funded B Warrants are subject to the Pre-Funded B Warrants Blocker (defined in Item 4).

     

    Includes 211,782 shares of Common Stock underlying certain C Warrants (defined in Item 4) owned by BVF. Excludes 2,939,478 shares of Common Stock underlying the C Warrants due to the C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

     

    Excludes 500,000 shares of Common Stock underlying certain Pre-Funded C Warrants (defined in Item 4) due to the Pre-Funded C Warrants Blocker (defined in Item 4) owned by the Reporting Persons.

    11

    CUSIP No. 372427401

    Item 1(a).Name of Issuer:

     

    Genocea Biosciences, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    100 Acorn Park Drive

    Cambridge, MA 02140

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    12

    CUSIP No. 372427401

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    372427401

     

    13

    CUSIP No. 372427401

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on December 31, 2020, the Reporting Persons hold 624,998 warrants, exercisable for an aggregate of 312,498 shares of Common Stock (the “Warrants”). Two Warrants entitle the holder thereof to acquire, for an exercise price of $9.60, one share of Common Stock. The Warrants are only exercisable to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would not beneficially own more than 9.99% of the outstanding shares of Common Stock after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Warrants (the “Warrants Blocker”). As of December 31, 2020, the Warrants Blocker does not limit the exercise of the Warrants by the Reporting Persons.

     

    14

    CUSIP No. 372427401

    As of the close of business on December 31, 2020, the Reporting Persons hold 217,617 Class B Warrants (the “B Warrants”) exercisable for an aggregate of 217,617 shares of Common Stock. The B Warrants have an exercise price of $4.5248 per share, subject to the terms of the B Warrants, and expire on February 14, 2024. The B Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding (the “B Warrants Blocker”). As of December 31, 2020, the B Warrants Blocker does not limit the exercise of the B Warrants by the Reporting Persons.

     

    As of the close of business on December 31, 2020, the Reporting Persons hold 531,248 Class B Pre-Funded Warrants (the “Pre-Funded B Warrants”) exercisable for an aggregate of 531,248 shares of Common Stock. The Pre-Funded B Warrants are pre-funded warrants and have an exercise price of $0.01 per share and expire on February 14, 2039. The Pre-Funded B Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding (the “Pre-Funded B Warrants Blocker”). As of December 31, 2020, the Pre-Funded B Warrants Blocker does not limit the exercise of the Pre-Funded B Warrants by the Reporting Persons.

     

    As of the close of business on December 31, 2020, the Reporting Persons hold 3,151,260 Class C Warrants (the “C Warrants”) exercisable for an aggregate of 3,151,260 shares of Common Stock. The C Warrants have an exercise price of $2.25 per share, subject to the terms of the C Warrants, and expire on July 24, 2024. The C Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding (the “C Warrants Blocker”). As of December 31, 2020, the C Warrants Blocker limited the exercise of C Warrants by the Reporting Persons to 211,782 of the 3,151,260 C Warrants held in the aggregate by the Reporting Persons, exercisable for an aggregate of 211,782 shares of Common Stock.

     

    As of the close of business on December 31, 2020, the Reporting Persons hold 500,000 Class C Pre-Funded Warrants (the “Pre-Funded C Warrants”) exercisable for an aggregate of 500,000 shares of Common Stock. The Pre-Funded C Warrants are pre-funded warrants and have an exercise price of $0.01 per share and have no expiration date. The Pre-Funded C Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding (the “Pre-Funded C Warrants Blocker”). As of December 31, 2020, the Pre-Funded C Warrants Blocker limited the exercise of the Pre-Funded C Warrants by the Reporting Persons to 0 of the 500,000 Pre-Funded C Warrants held in the aggregate by the Reporting Persons, exercisable for an aggregate of 0 shares of Common Stock.

     

    15

    CUSIP No. 372427401

    As of the close of business on December 31, 2020 (i) BVF beneficially owned 2,786,937 shares of Common Stock, including (a) 147,648 shares of Common Stock underlying certain Warrants held by it, 103,395 shares of Common Stock underlying certain B Warrants held by it, 252,407 shares of Common Stock underlying certain Pre-Funded B Warrants held by it and 211,782 shares of Common Stock underlying certain C Warrants held by it, and excluding (b) 1,479,683 shares of Common Stock underlying certain C Warrants held by it and 284,862 shares of Common stock underlying certain Pre-Funded C Warrants held by it; (ii) BVF2 beneficially owned 1,984,476 shares of Common Stock, including (a) 98,640 shares of Common Stock underlying certain Warrants held by it, 93,331 shares of Common Stock underlying certain B Warrants held by it and 227,841 shares of Common Stock underlying certain Pre-Funded B Warrants held by it, and excluding (b) 1,234,286 shares of Common Stock underlying certain C Warrants held by it and 227,841 shares of Common stock underlying certain Pre-Funded C Warrants held by it; and (iii) Trading Fund OS beneficially owned 347,804 shares of Common Stock, including (a) 25,318 shares of Common Stock underlying certain Warrants held by it, 13,350 shares of Common Stock underlying certain B Warrants held by it and 32,590 shares of Common Stock underlying certain Pre-Funded B Warrants held by it, and excluding (b) 208,701 shares of Common Stock underlying certain C Warrants held by it and 37,426 shares of Common stock underlying certain Pre-Funded C Warrants held by it.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,786,937 shares of Common Stock beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,984,476 shares of Common Stock beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 347,804 shares of Common Stock beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 4,771,413 shares of Common Stock beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 5,285,549 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, including 166,332 shares of Common Stock, which includes (a) 40,892 shares of Common Stock underlying certain Warrants, 7,541 shares of Common Stock underlying certain B Warrants and 18,410 shares of Common Stock underlying certain Pre-funded B Warrants, and excludes (b) 16,808 shares of Common Stock underlying certain C Warrants and 3,561 shares of Common stock underlying certain Pre-Funded C Warrants held in certain Partners Managed Accounts (the “Partners Managed Accounts”).

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 5,285,549 shares of Common Stock beneficially owned by Partners.

     

    16

    CUSIP No. 372427401

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 5,285,549 shares of Common Stock beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. BVF GP disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    (b)Percent of class:

     

    The following percentages are based on a denominator which is the sum of: (i) 51,635,257 shares of Common Stock outstanding as of October 27, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2020, (ii) certain or all of the 312,498 shares of Common Stock underlying the Warrants, as applicable, (iii) certain or all of the 217,617 shares of Common Stock underlying the B Warrants, as applicable, (iv) certain or all of the 531,248 shares of Common Stock underlying the Pre-Funded B Warrants, as applicable, and (v) 211,782 shares of Common Stock underlying the C Warrants, as applicable.

     

    As of the close of business on December 31, 2020, (i) BVF beneficially owned approximately 5.32% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 3.81% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock, (iv) BVF GP may be deemed to beneficially own approximately 5.32% of the outstanding shares of Common Stock, (v) BVF2 GP may be deemed to beneficially own approximately 3.81% of the outstanding shares of Common Stock, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, (vii) BVF GPH may be deemed to beneficially own approximately 9.04% of the outstanding shares of Common Stock, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding shares of Common Stock (less than 1% of the outstanding shares of Common Stock are held in the Partners Managed Accounts).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    17

    CUSIP No. 372427401

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by Trading Fund OS and the Partners Managed Accounts.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to Amendment No. 2 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2020.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    18

    CUSIP No. 372427401

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021 

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

    19

    Get the next $GNCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNCA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Duvall Diantha sold $81 worth of shares (1,355 units at $0.06), decreasing direct ownership by 2% to 75,388 units to satisfy tax liability

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:13:21 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Flechtner Jessica Baker sold $95 worth of shares (1,578 units at $0.06), decreasing direct ownership by 2% to 89,027 units (withholding obligation)

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:12:24 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Clark William D sold $241 worth of shares (4,023 units at $0.06), decreasing direct ownership by 1% to 304,377 units to satisfy withholding tax

      4 - GENOCEA BIOSCIENCES, INC. (0001457612) (Issuer)

      6/3/22 4:11:27 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genocea Announces Wind Down of Operations and Delisting From NASDAQ

      CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company's ongoing operations and terminate the Company's remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the Nasdaq Capital Market in connection with the wind down of its operations. The Company plans to file a Form 25 with the Securities and Exchange Commission on or about June 2

      5/24/22 8:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

      CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company, merger or reverse merger. As we pursue strategic alternatives, the Company has put into place a restructuring plan which includes an approximate 65% reduction in workforce in the second q

      4/28/22 4:05:10 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

          GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4:30 pm ET today to further discuss data CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation n

      4/8/22 1:05:00 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    SEC Filings

    See more
    • SEC Form 15-12B filed by Genocea Biosciences Inc.

      15-12B - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 5:21:30 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Genocea Biosciences Inc.

      EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 12:15:11 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Genocea Biosciences Inc.

      EFFECT - GENOCEA BIOSCIENCES, INC. (0001457612) (Filer)

      6/13/22 12:15:07 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Financials

    Live finance-specific insights

    See more
    • Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

      CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 1066689. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will

      3/3/22 8:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea Provides Third Quarter 2021 Corporate Update

      GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the third quarter ended September 30, 2021. "We continue to make significant progress. Most notably, we are very excited about our TiTAN™ clinical trial for GEN-011, our neoantigen-targeted peripheral T cell therapy (NPT) candidate, from which we expect to have initial data from a small subset of patient

      10/28/21 7:00:00 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast

      CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28th at 8:30 a.m. E.T. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8729366. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A webcast replay will be available on the Genocea we

      10/21/21 4:30:00 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GNCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13D/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13D/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      5/27/22 4:34:16 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      2/14/22 4:09:41 PM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genocea Biosciences Inc. (Amendment)

      SC 13G/A - GENOCEA BIOSCIENCES, INC. (0001457612) (Subject)

      2/14/22 6:19:47 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Genocea Biosciences with a new price target

      SVB Leerink reiterated coverage of Genocea Biosciences with a rating of Outperform and set a new price target of $6.00 from $5.00 previously

      4/6/21 7:42:43 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Genocea Biosciences with a new price target

      Needham reiterated coverage of Genocea Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      2/11/21 11:14:26 AM ET
      $GNCA
      Biotechnology: Pharmaceutical Preparations
      Health Care